England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback